FDA Breakthrough Therapy
Spruce Biosciences Surges on FDA Breakthrough: Is SPRB’s Rally Sustainable?
Spruce Biosciences (SPRB) stock soared after its lead therapy for Sanfilippo Syndrome Type B received FDA Breakthrough Therapy status. But can the momentum last amid financial strain and execution risks?